Insulin Lispro

Humalog / Admelog / Lyumjev

Insulin lispro was the first rapid-acting 'analog' insulin, approved in 1996. It is human insulin with a tiny engineered change: the order of two amino acids near the end of the B-chain (proline at B28 and lysine at B29) is reversed — hence 'lis-pro.' That swap does not change how insulin works once it reaches the receptor, but it weakens the tendency of insulin molecules to self-associate into hexamers in the vial and under the skin. Because insulin has to break down into single molecules to be absorbed, reducing that clumping lets lispro enter the bloodstream faster. The practical result is a mealtime (prandial) insulin with a quick onset (roughly 15 minutes) and a shorter duration than human Regular insulin, so it can be injected just before eating rather than half an hour ahead, and it better matches the glucose spike from a meal. This convenience and tighter timing are why rapid-acting analogs became the standard bolus insulin in intensive regimens and insulin pumps. Newer ultra-rapid formulations of lispro (Lyumjev) add excipients to speed absorption further. Lispro is used in type 1 and type 2 diabetes as the mealtime component of basal-bolus therapy, paired with a long-acting basal insulin or delivered continuously by pump. Like all insulins its central risk is hypoglycemia, and its faster action means the timing relative to food matters. It is a prescription medicine used under medical guidance; biosimilar versions (such as Admelog) have improved access. It is not interchangeable dose-for-dose with basal insulins and is not a wellness product.